AMGN
AMGN
Indicative, may be delayed. Not trading-grade data.
Recently viewed
Only on this browser · up to 5Ticker detail
AMGN
Cached quote, historical USD prices, and attributed headlines.
AI-generated
AI overview
Latest AMGN headlines
- Amgen (AMGN) receives renewed attention following Phase 3 trial successes amid a high valuation narrative [4]. - Broader market coverage notes stock sell-offs and futures activity involving Apple and Palantir [1][3]. - A separate growth-and-income stock analysis does not name Amgen [2].
Generated Nov 01, 2026 · 10:56 UTC
- Dow Jones Futures Loom After Stock Market Sell-Off; Apple, Palantir, Midterm Elections In Focus — Yahoo Finance
- Looking For Growth, Income, and Stability? This Stock Could Offer All 3 — Yahoo Finance
- Dow Jones Futures: Stock Market Sells Off As Apple, Palantir, Midterm Elections Loom; What To Do — Yahoo Finance
- Amgen (AMGN) Gets A Fresh Look As Phase 3 Wins Meet A Pricey Narrative — Yahoo Finance
- New CFO Appointment Could Be A Big Moment For Mattel (MAT) — Yahoo Finance
Summary of the linked headlines, not full-article analysis. AI can make mistakes; verify the sources. Not investment advice.
Some history or news is missing or stale. Available cached data remains visible; background requests respect provider retry backoff. Reload this range to check again.
Historical price
23 observations · USD · Source: Yahoo Finance · Sep 30, 2026 · 13:30 UTC to Oct 30, 2026 · 13:30 UTC · latest observation may be incomplete.
News about AMGN
- Dow Jones Futures Loom After Stock Market Sell-Off; Apple, Palantir, Midterm Elections In Focus ↗
- Looking For Growth, Income, and Stability? This Stock Could Offer All 3 ↗
- Dow Jones Futures: Stock Market Sells Off As Apple, Palantir, Midterm Elections Loom; What To Do ↗
- Amgen (AMGN) Gets A Fresh Look As Phase 3 Wins Meet A Pricey Narrative ↗
- New CFO Appointment Could Be A Big Moment For Mattel (MAT) ↗
- Big Homes, Big Loans ↗
- Stocks Fall Sharply on Intel and Amazon Sell-offs and Crypto Heist ↗
- Regeneron Soars 12% on Dupixent-Fueled Q3 Beat: “One of Our Strongest Years Ever” ↗
- AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock ↗
- AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth ↗
- How to Build $6,800 a Month in Dividend Income Without Selling a Single Share ↗
- What Sent Eli Lilly Stock Higher? ↗
- Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know ↗
- Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians ↗
- Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates ↗
- Caterpillar Revenue Miss, Outlook Dig Hole For Dow Jones Industrial Average ↗
- Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming? ↗
- AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS ↗
- AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND ↗
- AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 ↗
Comments and bookmarks
Comments are plain text from NPDev accounts. Bookmarks stay private to the account that saved them.
No comments yet. Be the first to say something.
Sign in to join the conversation.